Abstract: In particular, some embodiments provide shunts having a plurality of individually actuatable flow control elements that can control the flow of fluid through associated ports and/or flow lumens. For example, each individually actuatable flow control element can be actuated to modify a flow of a corresponding port and/or flow lumen. The individually actuatable flow control elements may be actuated along a given actuation axis. A flow control assembly may include a plurality of flow control elements arranged about a collection region. Accordingly, the shunts described herein can be manipulated into a variety of configurations that provide different drainage rates based on a degree to which the ports and/or flow lumens are blocked or unblocked, therefore providing a titratable glaucoma therapy for draining aqueous from the anterior chamber of the eye.

Abstract: The present technology relates to intraocular shunting systems and methods. In some embodiments, the present technology includes intraocular shunting systems that include a drainage element having an inflow portion configured for placement within an anterior chamber of the eye outside of an optical field of view of the patient and an outflow portion configured for placement at a different location of the eye. The system can also include a flow control assembly having a rotational control element operably coupled to the drainage element. The flow control assembly can further include an actuation structure coupled to the rotational control element and configured to selectively change an orientation of the rotational control element. An amount of fluid through the inflow portion and/or the outflow portion can vary based on the selected orientation of the rotational control element.

Abstract: An access management system and method provisions credentials to access a resource, such as external web user accounts. Credentials are generated, encrypted and stored. To access the resource, encrypted credentials are decrypted, masked, and served to users, such that they are not visible to the user requiring access. The user is unaware of the credentials used to authenticate and unable to access the provisioned web resources outside set parameters.

Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.

Abstract: The present technology is directed to adjustable flow glaucoma shunts and methods for making and using such devices. In many of the embodiments described herein, the shunts include a generally flat frame. The frame can include an elongated portion having a lumen extending therethrough and a bladder portion defining an interior chamber that is in fluid communication with the lumen. When implanted in a patient's eye, aqueous can drain from the anterior chamber to a target outflow location via the lumen and interior chamber. In some embodiments, the shunts include a flow control assembly positioned within the interior chamber of the bladder portion to control the flow of aqueous through the lumen.

Abstract: Disclosed herein are methods and compositions for detecting Bordetella pertussis and Bordetella parapertussis by detecting the presence of the IS481 and IS1001 genomic insertion sequences, respectively.

Abstract: The present technology is directed to adjustable shunts for treating glaucoma. In particular, some embodiments provide shunts having a plurality of individually actuatable flow control elements that can control the flow of fluid through associated ports and/or flow lumens. For example, each individually actuatable flow control element can be actuated to block and/or unblock a corresponding port and/or flow lumen. Accordingly, the shunts described herein can be manipulated into a variety of configurations that provide different drainage rates based on whether the ports and/or flow lumens are blocked or unblocked, therefore providing a titratable glaucoma therapy for draining aqueous from the anterior chamber of the eye.

Abstract: A Type II superconductor includes a perforated carbonaceous material with an activating material on at least one surface. The activating material a non-polar liquid that does not incorporate Pi-bonding in its structure. The superconductor is manufactured by perforating a carbonaceous material to produce voids and coating at least one surface of the carbonaceous material with the activating material. A superconductive cable includes wires with a perforated carbonaceous material wetted with the activating material on a non-conductive substrate interspersed with non-conducting spacers and surrounded by an insulation layer. The superconductor conducts current at room temperature and above.

Abstract: The present invention relates to novel recombinant Bacillus megaterium cytochrome P450-monooxygenase (P450-BM3) variants for the C19 hydroxylation of steroids and derivatives thereof or for improved BM3 protein expression. In particular, the present invention also relates to methods and processes using P450-BM3 variants for the production of estrone and estradiol.

Abstract: The present technology is generally directed to adjustable shunting systems for draining fluid from a first body region to a second body region. The adjustable shunting systems include a flow control plate or cartridge for controlling the flow of fluid through the system. For example, the flow control plate can include a shape memory actuation assembly having one or more nitinol actuators for controlling the flow of fluid through the system. The flow control plate can further include a plurality of discrete sheets or layers adhered together to encase the shape memory actuation assembly. The discrete sheets or layers can form flow channels for directing fluid through the flow control plate.

Abstract: An apparatus for treating an aneurysm includes an occlusion element configured to be releasably coupled to an elongate delivery shaft and having a distal end, a proximal end, and a longitudinal axis extending between the distal end and the proximal end, the occlusion element configured to be delivered in a collapsed configuration and further configured to expand to an expanded configuration, the occlusion element comprising an inverted mesh tube having an outer layer and an inner layer, the outer layer transitioning to the inner layer at an inversion fold located at or adjacent the distal end of the occlusion element, the inversion fold defining an inner diameter, the occlusion element further comprising a maximum outer diameter, wherein the inner diameter is between about 35% to about 85% of the maximum outer diameter, and wherein an outer diameter of the occlusion element increases along the longitudinal axis to the maximum outer diameter.

Abstract: New dosing regimens for treating muscular dystrophy in a patient suffering from Duchenne muscular dystrophy (DMD) with an antisense oligonucleotide conjugate that causes skipping of an exon in the human dystrophin gene are described. Also described is a method of treating a patient with an antisense oligomer CPP conjugate and a magnesium supplement.

Abstract: A method for acoustic imaging includes emitting an acoustic signal. The method includes (a) emitting an acoustic signal; (b) detecting signals corresponding to reflections of the acoustic signal at an array of positions proximate a positon of the emitting; (c) adding, for a chosen distance from the position of the emitting, a respective time delay to each detected signal to cause each detected signal to correspond to each of a plurality of positions in a plane transverse to a line normal to a plane of the array of positions; (d) summing the time delayed signals; (e) selecting one of the plurality of positions having a highest summed, delayed signal amplitude; and (f) assigning a pixel to the one of the plurality of positions having the highest amplitude. (b) through (f) are repeated for a plurality of different chosen distances.

Abstract: Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3? (CD3) provided herein, in treating, preventing or managing multiple myeloma.

Abstract: A mobile pet carrier having a base, first side, second side, third side, fourth side, and top member; and an interior compartment sized to hold an animal; the first side member defining a first side opening that provides access to the interior compartment through the first side member and having a first side opening cover; the top member defining a top opening that provides access to the interior compartment and having a top opening cover; the second side member defining a second side opening that provides access to the interior compartment and having a second side opening cover; the third side member having a side compartment that has a foldable panel movable between a closed position and an open position; and where, in the open position, a mesh portion of the third side member is exposed to provide ventilation to the interior compartment.

Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.

Abstract: A scalable cache coherency protocol for system including a plurality of coherent agents coupled to one or more memory controllers is described. The memory controller may implement a precise directory for cache blocks from the memory to which the memory controller is coupled. Multiple requests to a cache block may be outstanding, and snoops and completions for requests may include an expected cache state at the receiving agent, as indicated by a directory in the memory controller when the request was processed, to allow the receiving agent to detect race conditions. In an embodiment, the cache states may include a primary shared and a secondary shared state. The primary shared state may apply to a coherent agent that bears responsibility for transmitting a copy of the cache block to a requesting agent. In an embodiment, at least two types of snoops may be supported: snoop forward and snoop back.

Abstract: Provided herein are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing multiple myeloma. The second active agent is one or more of a BTK inhibitor, an mTOR inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an MEK inhibitor, an XPO1 inhibitor, a DOT1L inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a BRD4 inhibitor, a PLK 1 inhibitor, an NEK2 inhibitor, an AURKB inhibitor, a BIRC5 inhibitor, a BET inhibitor, or a DNA methyltransferase inhibitor.

Abstract: A therapy system includes a patient support apparatus and a pneumatic therapy device that is coupleable to the patient support apparatus. The therapy device may receive power and air flow from the patient support apparatus.